Upgrade to SI Premium - Free Trial

Abbvie (ABBV) PT Lowered to $71 at BMO Capital

November 5, 2018 8:47 AM
BMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles